Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: radiation dose to the testes

Journal Article · · Nuclear Medicine Communications
; ; ; ; ; ; ;

Purpose: To investigate radiation doses to the testes delivered by a radiolabeled anti-CD20 antibody and its effects on male sex hormone levels. Materials and methods: Testicular uptake and retention of 131I-tositumomab were measured, and testicular absorbed doses were calculated for 67 male patients (54+/-11 years of age) with non-Hodgkin's lymphoma who had undergone myeloablative radioimmunotherapy (RIT) using 131I-tositumomab. Time-activity curves for the major organs, testes, and whole body were generated from planar imaging studies. In a subset of patients, male sex hormones were measured before and 1 year after the therapy. Results: The absorbed dose to the testes showed considerable variability (range=4.4-70.2 Gy). Pretherapy levels of total testosterone were below the lower limit of the reference range, and post-therapy evaluation demonstrated further reduction [4.6+/-1.8 nmol/l (pre-RIT) vs. 3.8+/-2.9 nmol/l (post-RIT), P<0.05]. Patients receiving higher radiation doses to the testes (>=25 Gy) showed a greater reduction [4.7+/-1.6 nmol/l (pre-RIT) vs. 3.3+/-2.7 nmol/l (post-RIT), P<0.05] compared with patients receiving lower doses (<25 Gy), who showed no significant change in total testosterone levels. Conclusion: The testicular radiation absorbed dose varied highly among individual patients. Finally, patients receiving higher doses to the testes were more likely to show post-RIT suppression of testosterone levels.

Research Organization:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC05-76RL01830
OSTI ID:
1054838
Report Number(s):
PNNL-SA-86954; 600306000
Journal Information:
Nuclear Medicine Communications, Journal Name: Nuclear Medicine Communications Journal Issue: 12 Vol. 33; ISSN 0143-3636
Country of Publication:
United States
Language:
English

Similar Records

Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma using 131I Tositumomab to that of Other Types of Non-Hodgkin's Lymphoma
Journal Article · Tue Nov 30 23:00:00 EST 2004 · Cancer Biotherapy & Radiopharmaceuticals · OSTI ID:15015214
Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin’s Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose
Journal Article · Thu May 01 00:00:00 EDT 2008 · Journal of Nuclear Medicine, 49(5):837-844 · OSTI ID:934400
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for Adults ≥ 60 Years Old with Relapsed or Refractory B-Cell Lymphoma
Journal Article · Tue Apr 10 00:00:00 EDT 2007 · Journal of Clinical Oncology, 25(11):1396-1402 · OSTI ID:909996

Related Subjects

I-tositumomab
follicular lymphoma
radioimmunotheraphy
radiation dosimetry
male sex hormones